These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 9606450

  • 21. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P.
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [Abstract] [Full Text] [Related]

  • 22. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW, Schultz JS, O'Donnell JC, Patel PA, Sasane RM.
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [Abstract] [Full Text] [Related]

  • 23. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G, Park C, Lee H, Han E, Kim DS, Jang S.
    BMC Health Serv Res; 2014 Mar 03; 14():100. PubMed ID: 24589172
    [Abstract] [Full Text] [Related]

  • 24. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C, Ruff L, Balu S.
    J Med Econ; 2013 Jul 03; 16(7):907-16. PubMed ID: 23641809
    [Abstract] [Full Text] [Related]

  • 25. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA.
    JAMA; 1995 Apr 05; 273(13):1032-8. PubMed ID: 7897787
    [Abstract] [Full Text] [Related]

  • 26. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR, Yin D, Alemao E, Drummond M.
    Pharmacoeconomics; 2004 Apr 05; 22 Suppl 3():37-48. PubMed ID: 15669152
    [Abstract] [Full Text] [Related]

  • 27. The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder.
    Loh WJ, Watts GF.
    Curr Atheroscler Rep; 2023 Feb 05; 25(2):43-53. PubMed ID: 36609642
    [Abstract] [Full Text] [Related]

  • 28. Timing of intake of lipid lowering drugs: is that of importance?
    Hanefeld M.
    Klin Wochenschr; 1989 May 02; 67(9):511-2. PubMed ID: 2733381
    [No Abstract] [Full Text] [Related]

  • 29. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 02; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 30. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
    Shrank WH, Barlow JF, Brennan TA.
    JAMA; 2015 Oct 13; 314(14):1443-4. PubMed ID: 26258765
    [No Abstract] [Full Text] [Related]

  • 31. [Statines for all or individualized lipid lowering therapy?].
    Parhofer K.
    MMW Fortschr Med; 2009 Apr 02; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
    [No Abstract] [Full Text] [Related]

  • 32. I am among the minority of people who have experienced serious side effects from using a statin. Along with healthy lifestyle choices, are there any other non-statin medications that can help?
    Heart Advis; 2010 Nov 02; 13(11):8. PubMed ID: 22834059
    [No Abstract] [Full Text] [Related]

  • 33. Interview: role of managed care in implementing NCEP-ATP III guidelines.
    Carver JC.
    Am J Manag Care; 2002 Jul 02; Suppl Symposium Reporter():7. PubMed ID: 12608153
    [No Abstract] [Full Text] [Related]

  • 34. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
    Kumar R, Tonkin A, Liew D, Zomer E.
    Int J Cardiol; 2018 Sep 15; 267():183-187. PubMed ID: 29731350
    [Abstract] [Full Text] [Related]

  • 35. [Fibrate and statine myopathy].
    Finsterer J.
    Nervenarzt; 2003 Feb 15; 74(2):115-22. PubMed ID: 12596012
    [Abstract] [Full Text] [Related]

  • 36. Lipid-lowering with statins and fibrinolytic parameters.
    Jovin IS, Heidinger K, Taborski U, Muller-Berghaus G.
    Eur Heart J; 1997 Sep 15; 18(9):1516. PubMed ID: 9458463
    [No Abstract] [Full Text] [Related]

  • 37. Shifting views on lipid lowering therapy.
    Krumholz HM, Hayward RA.
    BMJ; 2010 Jul 28; 341():c3531. PubMed ID: 20667950
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of low-density-lipoprotein lowering with statins.
    Rosenson RS, Stein JH.
    Lancet; 1994 Sep 03; 344(8923):683. PubMed ID: 7915366
    [No Abstract] [Full Text] [Related]

  • 39. By the way, doctor. I have high cholesterol, and have been taking Mevacor (lovastatin) for two years. Recently, I was switched to Pravachol (pravastatin) because my insurance company would no longer pay for Mevacor. Is it as good?
    Nicholson CR.
    Harv Womens Health Watch; 1999 Jun 03; 6(10):8. PubMed ID: 10233830
    [No Abstract] [Full Text] [Related]

  • 40. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC, Wang HH, Liu KS.
    Int J Clin Pract; 2011 Dec 03; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.